{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:55:20Z","timestamp":1792652120686,"version":"4.5.0"},"reference-count":59,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>There has been a widespread adoption of hypomethylating agents (HMA: 5-Azacytidine (5-Aza)\/decitabine) and venetoclax (Ven) for the treatment of acute myeloid leukemia (AML); however, the mechanisms behind the combination\u2019s synergy are poorly understood. Monotherapy often encounters resistance, leading to suboptimal outcomes; however, the combination of HMA and Ven has demonstrated substantial improvements in treatment responses. This study elucidates multiple synergistic pathways contributing to this enhanced therapeutic effect. Key mechanisms include HMA-mediated downregulation of anti-apoptotic proteins, notably MCL-1, and the priming of cells for Ven through the induction of genes encoding pro-apoptotic proteins such as Noxa. Moreover, Ven induces sensitization to HMA, induces overcoming resistance by inhibiting the DHODH enzyme, and disrupts antioxidant pathways (Nrf2) induced by HMA. The combination further disrupts oxidative phosphorylation in leukemia stem cells, amplifying the therapeutic impact. Remarkably, clinical studies have revealed a favorable response, particularly in patients harboring specific mutations, such as IDH1\/2, NPM1, CEBPA, or ASXL1. This prompts future studies to explore the nuanced underpinnings of these synergistic mechanisms in AML patients with these molecular signatures.<\/jats:p>","DOI":"10.3390\/ijms25010484","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T09:15:11Z","timestamp":1703841311000},"page":"484","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of Resistance"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5631-1164","authenticated-orcid":false,"given":"Rahul","family":"Mishra","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Anne Arundel Medical Center, Annapolis, MD 21401, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maedeh","family":"Zokaei Nikoo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhusha","family":"Veeraballi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"key":"ref_1","unstructured":"(2023, October 29). Key Statistics for Acute Myeloid Leukemia (AML). Available online: https:\/\/www.cancer.org\/cancer\/types\/acute-myeloid-leukemia\/about\/key-statistics.html."},{"key":"ref_2","unstructured":"FDA (2023, September 24). FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute Myeloid Leukemia. 11 June 2021, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1080\/14656566.2017.1349100","article-title":"Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: Alternatives in the frontline and relapse settings","volume":"18","author":"Uy","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: Mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/BF02135399","article-title":"5-Azacytidine, a new, highly effective cancerostatic","volume":"20","year":"1964","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/PPO.0000000000000664","article-title":"Overview of the Management of Higher-Risk Myelodysplastic Syndromes","volume":"29","author":"Singh","year":"2023","journal-title":"Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer: From pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/ajh.25978","article-title":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients","volume":"95","author":"Morsia","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of Venetoclax and Azacitidine in Treatment-Na\u00efve Patients with Acute Myeloid Leukemia and IDH1\/2 Mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1182\/blood.2023020102","article-title":"Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML","volume":"142","author":"Xie","year":"2023","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: Mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41375-019-0485-x","article-title":"Genetic characterization of ABT-199 sensitivity in human AML","volume":"34","author":"Bisaillon","year":"2020","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ajh.25146","article-title":"Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","article-title":"FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation","volume":"114","author":"Yoshimoto","year":"2009","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1038\/sj.onc.1202796","article-title":"IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line","volume":"18","author":"Dumon","year":"1999","journal-title":"Oncogene"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1038\/bcj.2012.5","article-title":"Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies","volume":"2","author":"Kasper","year":"2012","journal-title":"Blood Cancer J."},{"key":"ref_24","first-page":"708","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kontro","year":"2019","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.leukres.2014.08.016","article-title":"The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome","volume":"39","author":"Wu","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/leu.2013.330","article-title":"Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine","volume":"28","author":"Valencia","year":"2014","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1038\/s41375-020-0973-z","article-title":"Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia","volume":"34","author":"Gruber","year":"2020","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2008-02-140038","article-title":"Mechanisms of resistance to 5-aza-2\u2032-deoxycytidine in human cancer cell lines","volume":"113","author":"Qin","year":"2009","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"14040","DOI":"10.1002\/jcp.28091","article-title":"The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML","volume":"234","author":"Nguyen","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41467-018-03513-4","article-title":"RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia","volume":"9","author":"Cheng","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/ejh.13492","article-title":"Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML","volume":"105","author":"Hormi","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/leu.2014.44","article-title":"BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies","volume":"28","author":"Bogenberger","year":"2014","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Jeyaraju, D.V., Alapa, M., Polonskaia, A., Risue\u00f1o, A., Subramanyam, P., Anand, A., Ghosh, K., Kyriakopoulos, C., Hemerich, D., and Hurren, R. (Haematologica, 2023). Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase, Haematologica, Epub ahead of printing.","DOI":"10.3324\/haematol.2023.283437"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"13291","DOI":"10.1074\/jbc.R900010200","article-title":"The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress","volume":"284","author":"Nguyen","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00204-011-0674-5","article-title":"The cytoprotective role of the Keap1-Nrf2 pathway","volume":"85","author":"Baird","year":"2011","journal-title":"Arch. Toxicol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/hematolrep15010010","article-title":"Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells","volume":"15","author":"Hu","year":"2023","journal-title":"Hematol. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1158\/2767-9764.CRC-22-0259","article-title":"Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia","volume":"3","author":"Kamachi","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","article-title":"How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia","volume":"33","author":"Jonas","year":"2019","journal-title":"Leukemia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3324\/haematol.2020.272609","article-title":"Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia","volume":"107","author":"Cojocari","year":"2021","journal-title":"Haematologica"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Nakajima, W., Miyazaki, K., Sakaguchi, M., Asano, Y., Ishibashi, M., Kurita, T., Yamaguchi, H., Takei, H., and Tanaka, N. (2022). Epigenetic Priming with Decitabine Augments the Therapeutic Effect of Cisplatin on Triple-Negative Breast Cancer Cells through Induction of Proapoptotic Factor NOXA. Cancers, 14.","DOI":"10.3390\/cancers14010248"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Xia, S., Hollingsworth, L.R., and Wu, H. (2020). Mechanism and Regulation of Gasdermin-Mediated Cell Death. Cold Spring Harb. Perspect. Biol., 12.","DOI":"10.1101\/cshperspect.a036400"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1186\/s12967-023-04481-0","article-title":"Antileukemic effect of venetoclax and hypomethylating agents via caspase-3\/GSDME-mediated pyroptosis","volume":"21","author":"Ye","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41375-020-1003-x","article-title":"Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network","volume":"35","author":"Gu","year":"2020","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-143200","article-title":"Venetoclax Inhibition of Pyrimidine Synthesis Guides Methods for Integration with Decitabine or 5-Azacytidine That Are Non-Myelosuppressive","volume":"136","author":"Gu","year":"2020","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.3324\/haematol.2020.254482","article-title":"Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation","volume":"105","author":"Saunthararajah","year":"2020","journal-title":"Haematologica"},{"key":"ref_50","unstructured":"FDA (2023, September 24). FDA Approves Venetoclax in Combination for AML in Adults. 20 December 2019, Available online: https:\/\/www.fda.gov\/drugs\/fda-approves-venetoclax-combination-aml-adults."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2019-128373","article-title":"Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression","volume":"134","author":"Chyla","year":"2019","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1182\/blood-2022-167967","article-title":"Molecular Predictors of Response and Survival in Patients with Relapsed\/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy","volume":"140","author":"Johnson","year":"2022","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3324\/haematol.2022.281214","article-title":"Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-na\u00efve acute myeloid leukemia","volume":"107","author":"Gangat","year":"2022","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/joim.13581","article-title":"Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia","volume":"293","author":"Weng","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1080\/10428194.2023.2173523","article-title":"Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease","volume":"64","author":"Sanber","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"ref_58","unstructured":"Faruqi, A., and Tadi, P. (2023, October 28). Cytarabine, StatPearls [Internet], Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557680\/."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2217\/pgs-2016-0055","article-title":"Pharmacogenomics and the treatment of acute myeloid leukemia","volume":"17","author":"Montesinos","year":"2016","journal-title":"Pharmacogenomics"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/1\/484\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:44:20Z","timestamp":1760132660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/1\/484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["ijms25010484"],"URL":"https:\/\/doi.org\/10.3390\/ijms25010484","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,29]]}}}